107759-58-0Relevant articles and documents
Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer
Alexoff, David,Choi, Seok Rye,Kung, Hank F.,Ploessl, Karl,Yao, Xinyue,Zha, Zhihao,Zhao, Ruiyue,Zhu, Lin
, (2020)
Radioligand therapy (RLT) using prostate-specific membrane antigen (PSMA) targeting ligands is an attractive option for the treatment of Prostate cancer (PCa) and its metastases. We report herein a series of radioiodinated glutamate-urea-lysine-phenylalan
RADIOHALIDE-LABELED TARGETED DIAGNOSTICS AND THERAPEUTICS
-
Paragraph 0158, (2016/03/22)
Disclosed are chemical entities of formula (I) wherein R1, R2 and n are defined herein, and methods of use thereof. These chemical entities are radiative emitters and are useful, e.g., as therapeutic agents for the treatment of, or as diagnostic (e.g., imaging) agents for cancers, e.g., cancers in which PARP1 is overexpressed.
Radiohalogenated for proteins
-
, (2008/06/13)
Haloaryl compounds bearing a defined functional group or precursor are metalated with either Sn(n-Bu)3 or SnMe3. The resulting aryltin compound may be transmetalated in site-specific reaction with one of the following organometallic